BRAF and Miyoshi myopathy: For example, based on preclinical data suggesting synergy between IFN-α and BRAF inhibitors in BRAF-mutated disease, two phase I/II clinical trials are currently evaluating the combination of IFN-α/peg-IFN-α and vemurafenib in BRAF-mutated MM (NCT01943422, NCT01959633).